Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionHolocene Advisors, LP
Latest Disclosed Ownership67,618 shares
Latest Disclosed Value $ 30,194,142
Holocene Advisors, LP ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Holocene Advisors, LP filed a 13F-HR form disclosing ownership of 67,618 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $30,194,142 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,478 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 4,474.97% during the quarter. The current value of the position is $28,963,494 USD.

Holocene Advisors, LP has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 67,618 66,140 4,474.97 30,194 4,406.57 0.0728
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,478 1,478 670 0.0014
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,216 -100.00 0 -100.00
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,216 0 0.00 541 -8.15 0.0013
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,216 -327 -21.19 590 -5.15 0.0017
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,543 1,543 621 0.0020
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -500,130 -100.00 0 -100.00
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 500,130 359 0.07 140,932 8.06 0.8512
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 499,771 499,771 130,425 0.6796
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -2,693 -100.00 0 -100.00
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,693 -3,078 -53.34 543 -56.21 0.0031
2021-05-17 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,771 1,997 52.91 1,240 39.01 0.0078
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,774 3,774 892 0.0056
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -118,153 -100.00 0 -100.00
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 118,153 -318,634 -72.95 34,301 -67.00 0.3006
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 436,787 -66,148 -13.15 103,933 -5.62 1.1161
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 502,935 64,252 14.65 110,118 48.16 0.9869
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 438,683 438,683 74,322 0.7652
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,346 -100.00 0 -100.00
2018-05-15 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,346 1,346 219 0.0049
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM Put 451,300 117,776 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.